Skip to main content
SpringerLink
Log in

“Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK”

How important is quality of life?

  • Commentary
  • Published:
The European Journal of Health Economics, formerly: HEPAC Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Arguedas MR, Heudebert GH, Stinnett AA, Wilcox CM (2002) Biliary Stents in malignant obstructive jaundice due to pancreatic carcinoma: a cost-effectiveness analysis. Am J Gastroenterol 97:898–904

    Article  PubMed  Google Scholar 

  2. Aristides M, Lees M, Botwood N, McKendrick J, Stephenson DA, Maniadakis N (2003) Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. Eur J Health Econom 4:216–221

    Article  Google Scholar 

  3. Chilcott J, Brennan A, Booth A, Karnon J, Tappenden P (2003) The role of modelling in prioritising and planning clinical trials. Health Technol Assess 7:23

    Google Scholar 

  4. O’Shaughnessy JA, Wittes RE, Burke G, Friedman MA, Johnson JR, Niederhuber JE, Rothenberg ML, Woodcock J, Chabner BA, Temple R (1991) Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J Clin Oncol 9:2225–2232

    CAS  PubMed  Google Scholar 

  5. Tappenden P, Chilcott J, Eggington S, Oakley J, McCabe C (2004) Methods for expected value of information analysis in complex health economic models: developments on the health economics of beta-interferon and glatiramer acetate for multiple sclerosis. Health Technol Assess (in press)

    Google Scholar 

Download references

Conflict of interest:

No information supplied.

Author information

Authors and Affiliations

  1. ScHARR Technology Assessment Group, School of Health and Related Research, University of Sheffield, Regent Court, 40 Regent Street, Sheffield, S1 4DA, UK

    Nick Bansback, Sue Ward & Jon Karnon

Authors
  1. Nick Bansback
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sue Ward
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jon Karnon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nick Bansback.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bansback, N., Ward, S. & Karnon, J. “Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK”. HEPAC 5, 188–189 (2004). https://doi.org/10.1007/s10198-004-0226-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-004-0226-5

Keywords

Search

Navigation